Company / Return on Assets (ROA)
Travere Therapeutics, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-4.2%
FY2025
5-year range
-54.1% / -4.2%
FY2021-FY2025
Trend
+92.2%
vs FY2024
Sector context
#73 of 213
Health Care
What the data says
At -4.2%, Travere Therapeutics, Inc.'s return on assets (roa) ranks #73 of 213 in the Health Care sector. Return on Assets (ROA) has fluctuated over the past 10 years, ranging from -54.1% in FY2024 to 22.5% in FY2017.
Based on SEC 10-K filings.
-4.2% in FY2025 with a 5-year CAGR of +12.7%.
Improved from -14.1% to -4.2% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +37.2pp
- 5-Year Change
- +12.7pp
- 10-Year Change
- -
Sector benchmark
#73 of 213 in Health CareTop 34% of 213This company -4.2% Sector average -24.1%
▼
+82.5% above sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 92.2% year-over-year.
- Currently 19.9pp above the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2017.
- Lowest return on assets (roa) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -4.2% | +92.2% |
| FY2024 | -54.1% | -283.3% |
| FY2023 | -14.1% | +65.9% |
| FY2022 | -41.4% | -119.6% |
| FY2021 | -18.9% | -11.5% |
| FY2020 | -16.9% | -71.1% |
| FY2019 | -9.9% | -46.4% |
| FY2018 | -6.8% | -130.0% |
| FY2017 | 22.5% | +206.7% |
| FY2016 | -21.1% | -192.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026